Jun 29, 05
|
| NEW STORY |
| 10:06 ET |
Market Strategies, Inc. Announces Genentech as Clear Winner at ASCO 2005 with Herceptin for Adjuvant Breast Cancer and Avastin for Lung Cancer as Two Most Important Cancer Drugs
|
|
May 19, 05
|
| 16:00 ET |
Onyx Pharmaceuticals to Webcast Analyst Briefing Meeting Scheduled for May 26, 2005
|
|
May 18, 05
|
| 15:41 ET |
Chromosome Deletion Predicts Aggressive Neuroblastoma
|
|
| 15:40 ET |
Radioactive Isotope Is Effective for Neuroblastoma
|
|
| 14:00 ET |
Guilford Pharmaceuticals Presents New NAALADase Inhibitor Data in Chemotherapy-Induced Neuropathy at ASCO
|
|
May 17, 05
|
| 15:45 ET |
Three US Oncology Network Practices Receive Clinical Trial Participation Awards at 2005 ASCO Annual Meeting
|
|
| 15:14 ET |
New Investigational Studies Showed Oral Hycamtin(R) (Topotecan Hydrochloride) Clinically Active in the Treatment of Small Cell and Non-Small Cell Lung Cancer
|
|
| 14:39 ET |
Guilford Pharmaceuticals Announces Promising Results at ASCO in Study of Newly Diagnosed High Grade Malignant Glioma
|
|
| 14:37 ET |
Cell Therapeutics, Inc. to Review XYOTAX(TM) Data from ASCO Meeting
|
|
| 08:30 ET |
Genta Announces Conference Call to Review First Quarter Highlights and Data Presented at the American Society of Clinical Oncology Annual Meeting
|
|
| 08:15 ET |
Multiple Presentations Report Active Combinations of Genasense(R) Plus Chemotherapy in Patients With Advanced Gastrointestinal Cancer
|
|
| 08:14 ET |
Xanthus Presents at ASCO: Phase 1 Data Shows Significant Activity of Amonafide in Combination With ara-C for Treatment of Poor Risk AML
|
|
| 08:10 ET |
Agennix's Oral Talactoferrin Improved Response Rates, Time to Progression and Duration of Response When Combined With First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
|
|
| 08:09 ET |
New Data Suggests Novel Maintenance Biotherapy Regimen Slows Disease Progression and Improves Overall Survival in Metastatic Melanoma Patients
|
|
| 08:07 ET |
Web Cast Announcing Promising News from ASCO for Early Breast Cancer Patients
|
|
| 08:05 ET |
Genasense(R) Combinations With Chemotherapy Reported for Children With Solid Tumors and Adults With Extensive-Stage Small Cell Lung Cancer
|
|
| 08:05 ET |
Preliminary Phase 1 Data Show MedImmune's Siplizumab Well Tolerated in CD2-Positive Lymphoma and Leukemia Patients
|
|
| 08:03 ET |
Immunicon Corporation Announces Presentation of Data on Circulating Tumor Cells versus Serum Tumor Markers in Metastatic Breast Cancer at the 2005 American Association of Clinical Oncology (ASCO) Annual Meeting
|
|
| 08:03 ET |
New Front-Line Data at ASCO in Multiple Myeloma Support Important Role of VELCADE(R) (bortezomib) for Injection
|
 |
| 08:01 ET |
Further Phase 2 Data Confirm Panitumumab Single-Agent Antitumor Activity in Patients With Metastatic Colorectal Cancer
|
|
| 08:00 ET |
Cell Genesys Reports Encouraging Follow-Up Data From Second Phase 2 Trial of GVAX(R) Vaccine for Prostate Cancer
|
|
| 08:00 ET |
Introgen's Nanoparticle Cancer Therapy INGN 401 Demonstrates Promise in the Treatment of Lung Cancer
|
|
| 00:01 ET |
Transgene's Therapeutic Vaccine MVA-MUC1-IL2 at ASCO:
|
|
May 16, 05
|
| 23:14 ET |
Results of PI-88 Phase II Clinical Trial in Melanoma Presented at ASCO
|
|
| 17:00 ET |
CuraGen and TopoTarget Announce Presentation of PXD101 Phase I Results at ASCO
|
|
| 14:02 ET |
Vion Presents Data on CLORETAZINE(TM) (VNP40101M) in Hematologic Malignancies at ASCO(R) Annual Meeting
|
|
| 14:00 ET |
Pharmacyclics Announces Presentation of Data at ASCO That Support Use of Neurologic Endpoint in Brain Metastases Studies
|
|
| 13:30 ET |
Cell Genesys Reports Additional Positive Data From Phase 2 Trial of GVAX(R) Vaccine for Leukemia
|
|
| 09:31 ET |
Once-Monthly Somatostatin Analogue Increases Overall Survival in Carcinoid Syndrome
|
|
| 09:07 ET |
Therion Announces Oral Presentation of Data from Phase II PROSTVAC-VF Study in Patients with Androgen-Independent Prostate Cancer at ASCO
|
|
| 08:36 ET |
Hybridon Announces Oral Presentation of Results for Phase I Trial of IMOxine(R) at ASCO 2005
|
|
| 08:06 ET |
Clinical Data Presented at ASCO Annual Meeting Demonstrates Activity of QUADRAMET(R) in Osteosarcoma
|
|
| 08:05 ET |
Genasense(R) Phase 3 Results in Malignant Melanoma Updated at ASCO
|
|
| 08:02 ET |
Vical Presents Design of Phase 3 Melanoma Trial at ASCO
|
|
| 08:00 ET |
Introgen's Novel p53 Cancer Vaccine Sensitizes Tumors to Platinum and Taxane Chemotherapies
|
|
| 07:51 ET |
New Promising Clinical Data Supports the Use of GV1001 in Lung Cancer and Leukaemia
|
|
| 07:45 ET |
ERBITUX(R) (Cetuximab) Scientific Data in Several Tumor Types Presented at ASCO Annual Meeting
|
|
| 07:32 ET |
SuperGen Reports Results of Phase III Rescue Study With Orathecin(TM) (Rubitecan Capsules) Versus 5-FU in Pancreatic Cancer Patients
|
|
| 06:45 ET |
Immunicon Corporation Announces Presentation of Data on Circulating Tumor Cells in 'Non-Measurable' Metastatic Breast Cancer at the 2005 American Association of Clinical Oncology (ASCO) Annual Meeting
|
|
| 06:01 ET |
Cytogen Announces Publication of Data from Phase II Study Evaluating Combination of QUADRAMET(R) with Chemotherapy in Prostate Cancer at ASCO
|
|
| 02:00 ET |
Cambridge Antibody Technology Announces Interim Results for the Six Months Ended 31 March 2005
|
|
| 00:01 ET |
Transgene Presents Updated Positive Phase II Data of Its Therapeutic Vaccine MVA-MUC1-IL2 In Prostate Cancer at Annual ASCO Meeting
|
|
May 15, 05
|
| 22:46 ET |
REVLIMID(R) (lenalidomide) Significantly Delays Time to Disease Progression in Previously Treated Multiple Myeloma Patients Presented at 2005 ASCO
|
|
| 22:32 ET |
REVLIMID(R) Study in Myelodysplastic Syndromes With Deletion 5Q Chromosomal Abnormality Presented at ASCO Plenary Session
|
|
| 22:26 ET |
REVLIMID(R)(Lenalidomide) Study in Chronic Lymphocytic Leukemia Presented at 2005 ASCO
|
|
| 11:45 ET |
Taxotere(R) Regimen Demonstrates Significant Survival Benefit in the Treatment of Advanced Gastric Cancer
|
|
| 08:36 ET |
GlaxoSmithKline Issues Update On Lapatinib: New Clinical Data And Regulatory Filing Plans
|
|
| 08:09 ET |
Therion Announces Presentation of Follow-up Clinical Data Regarding Its Novel Targeted Cancer Therapy PANVAC-VF at ASCO
|
|
| 08:00 ET |
Study Demonstrates ViroLogic's eTag System Can Measure Activated VEGF Receptor, Target for Anti-Angiogenic Treatments
|
|
| 07:55 ET |
Kosan Presents Favorable Data From Two KOS-862 Phase IB Chemotherapy Combination Clinical Trials at the American Society of Clinical Oncology Meeting
|
|
| 07:55 ET |
Kosan Presents Phase I Results on KOS-953 as Multiple Myeloma Treatment at American Society of Clinical Oncology Meeting
|
|
| 07:00 ET |
XYOTAX(TM) Significantly Prolongs Survival in Poor Performance Status (PS2) Non-small Cell Lung Cancer Patients Compared to Standard Treatment With Vinorelbine
|
|
May 14, 05
|
| 17:00 ET |
New Data Show Pfizer's SUTENT/SU11248 (sunitinib malate) Extends Overall Survival in Gleevec-resistant GIST
|
|
| 16:02 ET |
Phase III Study of Tarceva in Combination With Chemotherapy Improves Survival in Pancreatic Cancer Patients
|
|
| 15:37 ET |
Vaccine to Treat Nicotine Addiction Achieves Proof of Efficacy in Phase II Clinical Trial
|
|
| 15:36 ET |
XYOTAX in Combination with Radiation Produces Major Tumor Responses in 81 Percent of Patients with Esophageal or Gastric Cancer
|
|
| 15:27 ET |
XYOTAX in Combination with Carboplatin Produces Major Tumor Response in 98 Percent of First-line Ovarian Cancer Patients
|
|
| 11:17 ET |
Therion Announces Oral Presentation of Clinical Data on Its Targeted Cancer Therapy PROSTVAC-VF at ASCO
|
|
| 11:15 ET |
Dendreon D9901 Phase 3 Data Showing Provenge Significantly Improves Survival in Advanced Prostate Cancer Patients Presented at ASCO
|
|
| 10:00 ET |
Preliminary Analysis of Phase 2 Study Shows 53 Percent of Patients With Stage IV Metastatic Melanoma Survive One-Year Mark When Treated With Vitaxin(R)
|
|
| 08:01 ET |
Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented
|
|
| 08:00 ET |
Coley Pharmaceutical Group's Randomized Phase II Study Indicates that CPG 7909 has the Potential to Improve Overall Survival When Combined with Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
|
| 07:45 ET |
Researchers Announce Addition of Oxaliplatin to 5-FU Plus Leucovorin Improves Disease-Free Survival in Patients with Stage II and Stage III Colon Cancer
|
|
| 07:45 ET |
Sorafenib (BAY 43-9006) Doubles Progression-Free Survival in Phase III Kidney Cancer Trial
|
|
| 06:30 ET |
IMPAC Medical Systems and The Mattson Jack Group Announce Expanded Agreement
|
|
May 13, 05
|
| 18:00 ET |
Avastin Plus Chemotherapy Showed Doubling of Time Without Cancer Progression In Phase III Trial of First-Line Metastatic Breast Cancer Patients
|
|
| 17:46 ET |
Phase III Trial of Avastin Plus Chemotherapy Showed 30 Percent Improvement in Overall Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
|
|
| 17:34 ET |
Herceptin Plus Chemotherapy Improved Disease-Free Survival and Overall Survival in Adjuvant Setting for Early-Stage HER2-Positive Breast Cancer Patients
|
|
| 16:00 ET |
Letrozole Offers Greater Protection From Recurrence of Early Breast Cancer Than Tamoxifen, International Study Shows
|
|
| 13:00 ET |
Pharmacyclics Announces Publication of Interim Data From Study Evaluating Single Agent Xcytrin for Advanced Renal Cell Carcinoma at ASCO 2005
|
|
May 12, 05
|
| 16:00 ET |
Medarex Announces Webcast Discussion of 2005 ASCO Data and Recent Product Development Programs
|
|
| 08:31 ET |
FDA Grants SGX Orphan Drug Designation for Troxatyl(TM); SGX to Present Troxatyl(TM) Clinical Data at ASCO
|
|
May 11, 05
|
| 20:53 ET |
The Group Room(R) Cancer Talk Radio Show to Broadcast Live From the 41st Annual Meeting of the American Society of Clinical Oncology, Sunday, May 15
|
|
May 09, 05
|
| 16:02 ET |
Medarex Announces 2005 First Quarter Financial Results
|
|
| 08:38 ET |
Abbott to Present New Data on Its Oncology Pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 06, 05
|
| 08:01 ET |
Genta to Release First Quarter 2005 Financial Results on May 9, 2005
|
|
May 05, 05
|
| 08:31 ET |
Dendreon Announces D9901 Phase 3 Study Results for Provenge Immunotherapy to be Presented at ASCO
|
|
| 08:05 ET |
Genasense(R) Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
|
|
| 06:00 ET |
Cytogen Reports First Quarter 2005 Financial Results
|
|
May 04, 05
|
| 19:00 ET |
Genentech Announces Webcast Discussions of Data Presented at ASCO; Phase III Breast Cancer Studies to Be Presented at Educational Session
|
|
| 08:02 ET |
ViroLogic Announces Presentations on Its eTag Technology at the 2005 American Society of Clinical Oncology Annual Meeting (ASCO)
|
|
| 07:31 ET |
Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at the 2005 American Society of Clinical Oncology Annual Meeting
|
|
Apr 18, 05
|
| 08:58 ET |
Viragen to Present Data on Multiferon(R) Trial Results at 2005 ASCO Annual Meeting
|
|
| 07:08 ET |
Human Genome Sciences Reports Results of Phase 1 Clinical Trial of HGS-ETR1 in Patients With Advanced Solid Tumors
|
|
Apr 14, 05
|
| 08:30 ET |
Lexicon Genetics to Present at Upcoming Medical Meetings
|
|
Apr 05, 05
|
| 00:01 ET |
Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual Meeting
|
|